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DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Nonintegrin) is a C-type (Calcium dependent) lectin, 
expressed as homotetramers (presenting four copies of a Carbohydrate Recognition Domain (CRD) at the C-
terminus) on the surface of immature Dendritic Cells.i
[1]
 
Dendritic Cells (DCs) are one of the most important classes of Antigen Presenting Cells (APCs). They 
recognize many pathogens through several receptors such as DC-SIGN, MR, etc. After recognition, 
pathogens are internalized and DCs mature and migrate to lymph nodes.[2] Then, DCs relay the 
corresponding processing antigens as MHC complexes to naive T-cells, which differentiate allowing the 
appropriate immune response. Some of these pathogens, such as HIV, hijack this mechanism to infect the 
immune system cells: the pathogens are recognized by DCs but escape the processing pathway. Indeed, using 
DCs, HIV particles are finally transported, stabilised and presented in a fully native and infectious form to 
their target, the T-cells. 
The main carbohydrate ligand recognized by DC-SIGN is the high mannose glycan (Man)9(GlcNAc)2, also 
known as Man9, a branched oligosaccharide which is presented in multiple copies by several pathogen 
glycoproteins (gp120, GP1, …). Hence, a multivalent mannose display should be an adequate strategy to 
interact with this lectin with high affinity. 
In vivo, mannosides are normally hydrolyzed by mannosidases: the use of a structural mimic in place of the 
natural sugar could avoid the easy degradation in a biological environment. The aim of this project is to 
design and prepare products that meet these requirements. 
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Figure 1: The monovalent mimic 1 and the Boltorn dendrimer BH 30. 
 
So far, we have demonstrated, using NMR, that the monovalent mimic 1 shown in Figure 1 interacts with 
DC-SIGN. Also, this compound inhibits the DC-SIGN mediated infection in a pseudo-typed Ebola virus 
model.[3] Moreover, this molecule has been conjugated to a Boltorn-type dendrimer, leading to neo-
glycoconjugates that inhibit the binding of DC-SIGN to gp120 (envelope protein of HIV). 
In this communication we will report the synthesis of new monovalent inhibitors and the results of their 
binding assays by SPR. We will show also the synthesis of some multivalent compounds.  
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